TY - JOUR
T1 - Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis
AU - Yoon, Myeong Ho
AU - Reriani, Martin
AU - Mario, Gössl
AU - Rihal, Charanjit
AU - Gulati, Rajiv
AU - Lennon, Ryan
AU - Tilford, Jonella M.
AU - Lerman, Lilach O.
AU - Lerman, Amir
N1 - Funding Information:
The study was supported by grants from the NIH : NIH K24 HL-69840 , NIH R01 HL-63911 , HL-77131, HL 92954 , HL 085307 , DK 73608 , DK 77013 and the Mayo Foundation.
PY - 2013/9/30
Y1 - 2013/9/30
N2 - Aim: The purpose of the current study was to determine if long term treatment with an endothelin-A (ETA) receptor antagonist attenuates the progression of coronary plaques in patients with coronary endothelial dysfunction. Methods: Thirty-five patients with non-obstructive coronary disease and coronary endothelial dysfunction were randomized in a double blind manner to treatment with placebo or ETA receptor antagonist Atrasentan (10mg) for six months. Endothelial function was assessed by the change in coronary blood flow and coronary artery diameter in response to intracoronary acetylcholine. Normalized mean total atheroma volume (TAVMEAN), percent atheroma volume (PAV) and changes of atheroma volume were assessed by intravascular ultrasound (IVUS) at baseline and 6-month follow-up. Results: In segments with coronary endothelial dysfunction, there was a significant decrease in normalized TAVMEAN and PAV at six months from baseline in the Atrasentan group compared to the placebo group median (IQR) -2.00 mm3 (-7.28, 2.53.) vs 9.11 mm3 (1.23, 14.05), p=0.0024 and 0.955% (-3.43, 1.70) vs 3.85% (-0.39, 14.59) p=0.010. There was no change in normalized TAV or PAV in the segments with normal endothelial function. Conclusion: This study demonstrates that 6-month treatmentwith Atrasentan attenuates progression of coronary plaque in segments with endothelial dysfunction.
AB - Aim: The purpose of the current study was to determine if long term treatment with an endothelin-A (ETA) receptor antagonist attenuates the progression of coronary plaques in patients with coronary endothelial dysfunction. Methods: Thirty-five patients with non-obstructive coronary disease and coronary endothelial dysfunction were randomized in a double blind manner to treatment with placebo or ETA receptor antagonist Atrasentan (10mg) for six months. Endothelial function was assessed by the change in coronary blood flow and coronary artery diameter in response to intracoronary acetylcholine. Normalized mean total atheroma volume (TAVMEAN), percent atheroma volume (PAV) and changes of atheroma volume were assessed by intravascular ultrasound (IVUS) at baseline and 6-month follow-up. Results: In segments with coronary endothelial dysfunction, there was a significant decrease in normalized TAVMEAN and PAV at six months from baseline in the Atrasentan group compared to the placebo group median (IQR) -2.00 mm3 (-7.28, 2.53.) vs 9.11 mm3 (1.23, 14.05), p=0.0024 and 0.955% (-3.43, 1.70) vs 3.85% (-0.39, 14.59) p=0.010. There was no change in normalized TAV or PAV in the segments with normal endothelial function. Conclusion: This study demonstrates that 6-month treatmentwith Atrasentan attenuates progression of coronary plaque in segments with endothelial dysfunction.
KW - Endothelial function
KW - Endothelin receptor (ETA) antagonist
KW - Intravascular ultrasound (IVUS)
KW - Normalized mean total atheroma volume (TAVMEAN)
KW - Percent atheroma volume (PAV)
UR - http://www.scopus.com/inward/record.url?scp=84885325414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885325414&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2012.12.001
DO - 10.1016/j.ijcard.2012.12.001
M3 - Article
C2 - 23290081
AN - SCOPUS:84885325414
SN - 0167-5273
VL - 168
SP - 1316
EP - 1321
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 2
ER -